bioAffinity Technologies, Inc. (BIAF) Key Metrics
BIAF valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $4.8M
- Enterprise value
- $3.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.8
- Price / book
- 1.3
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- −1.25
BIAF key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsBIAF returns How much profit the business earns on the capital it uses.
BIAF financial health Debt, liquidity and how easily interest is covered.
BIAF efficiency & capital use Working capital cycle and where the cash goes.
BIAF returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
BIAF debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
BIAF cash returned to shareholders
BIAF key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Share price at fiscal year-end | $17.70 | $409.50 | $661.73 | $720.00 | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −301.8% | −242.4% | −99.8% | — | — | — | — |
| Return on invested capital (ROIC) | −335.0% | −214.0% | −360.6% | — | — | — | — |
| Return on assets (ROA) | −170.6% | −122.7% | −77.8% | −119.6% | −791.3% | — | −502.0% |
| Return on tangible assets | −168.7% | −208.6% | −132.6% | −66.9% | −435.3% | — | −502.0% |
| Free cash flow margin | −152.4% | −78.4% | −239.4% | — | — | — | — |
| Financial health | |||||||
| Total debt | $1.2M | $1.5M | $1.6M | $251,746 | $11.4M | $10.0M | $4.0M |
| Cash & short-term investments | $6.4M | $1.1M | $2.8M | $11.4M | $1.4M | $83,108 | $578,483 |
| Net debt | −$5.3M | $395,903 | −$1.2M | −$11.2M | $10.0M | $9.9M | $3.4M |
| Debt / equity | 0.16 | 0.58 | 0.33 | 0.02 | — | — | — |
| Debt / assets | 0.11 | 0.23 | 0.19 | 0.02 | 7.82 | 68.72 | 6.09 |
| Current ratio | 2.60 | 0.87 | 1.77 | 10.50 | 0.11 | 0.01 | 0.13 |
| Quick ratio | 2.58 | 0.86 | 1.76 | 10.50 | 0.10 | 0.01 | 0.13 |
| Interest coverage | -238.3 | -96.8 | -214.8 | -1.6 | -2.2 | -6.8 | -14.4 |
| Working capital | $4.7M | −$409,807 | $1.7M | $10.8M | −$11.6M | −$11.0M | −$4.1M |
| Invested capital | $2.0M | $3.0M | $3.6M | −$118,570 | −$5.8M | −$5.1M | −$603,018 |
| Tangible asset value | $5.2M | $422,411 | $2.6M | $11.0M | −$15.8M | −$15.1M | −$4.0M |
| Net current asset value | $3.9M | −$1.2M | $606,448 | $10.8M | −$15.8M | −$15.1M | −$4.1M |
| Capital allocation | |||||||
| Dividends paid | — | — | — | $185 | — | — | — |
| Share buybacks (net) | — | — | — | $185 | — | — | — |
| Capex / revenue | 1.0% | 0.8% | 0.9% | 4,580.2% | 0.2% | — | — |
| Capex / depreciation | 0.12 | 0.13 | 0.09 | 21.61 | 0.00 | 0.13 | 0.28 |
| Stock-based compensation / revenue | 10.9% | 10.6% | 29.6% | 5,175.8% | 3,293.4% | — | — |
| R&D / revenue | 33.9% | 19.0% | 68.1% | 31,733.7% | 87,132.5% | — | — |
| SG&A / revenue | 160.9% | 106.2% | 268.2% | 56,777.0% | 81,843.1% | — | — |
| Efficiency | |||||||
| Days sales outstanding | 49.8 | 38.0 | 59.3 | 456.7 | 427.6 | — | — |
| Days of inventory on hand | 3.1 | 1.4 | 2.5 | 30,241.9 | 3,796.2 | 465.3 | — |
| Days payables outstanding | 67.5 | 48.6 | 99.6 | 224,881.0 | 15,980.4 | 2,418.9 | 937.2 |
| Cash conversion cycle (days) | -14.5 | -9.1 | -37.8 | -194,182.5 | -11,756.6 | — | — |
| Receivables turnover | 7.33 | 9.60 | 6.16 | 0.80 | 0.85 | 0.00 | 0.00 |
| Payables turnover | 5.41 | 7.52 | 3.67 | 0.00 | 0.02 | 0.15 | 0.39 |
| Inventory turnover | 116.61 | 259.61 | 144.94 | 0.01 | 0.10 | 0.78 | — |
| Asset turnover | 0.71 | 1.27 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $840,583 | $975,439 | $411,082 | $6,010 | $1,530 | $1,530 | $1,530 |
| Average payables | $874,606 | $796,050 | $474,916 | $287,724 | $210,897 | $147,402 | $103,418 |
| Average inventory | $40,578 | $23,046 | $12,012 | $38,693 | $50,099 | $28,352 | — |
| Intangibles / total assets | 19.4% | 33.5% | 27.2% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from BIAF's annual financial statements (latest annual report filed March 16, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
BIAF valuation and financial ratios
bioAffinity Technologies earned a return on equity of −301.8% and a return on invested capital of −335.0% in fiscal 2025. It ended the year with $1.2 million of debt and $6.4 million in cash and short-term investments, a net cash position of $5.3 million.
See the BIAF income statement, the BIAF chart for price history, or the BIAF stock overview for the latest quote and news.
BIAF key metrics FAQ
What is bioAffinity Technologies's return on equity?
bioAffinity Technologies's return on equity (ROE) was −301.8% in fiscal 2025: net income of -$14.9 million on average shareholders' equity of $4.9 million.
What is bioAffinity Technologies's ROIC?
bioAffinity Technologies's return on invested capital was −335.0% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does bioAffinity Technologies have?
bioAffinity Technologies had total debt of $1.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.16 and more cash than debt.
What is bioAffinity Technologies's current ratio?
bioAffinity Technologies's current ratio was 2.60 at the end of fiscal 2025: current assets were 2.60 times current liabilities.